Beta-Blockers Pharmacology

Quick Answer

Beta-adrenergic receptor antagonists (beta-blockers) competitively inhibit catecholamine binding at beta-adrenoceptors, producing negative chronotropy (reduced heart rate), negative inotropy (reduced contractility), negative dromotropy (slowed AV conduction), and reduced renin release. Classification is based on receptor selectivity (beta-1 selective: metoprolol, atenolol, esmolol vs non-selective: propranolol, carvedilol, labetalol), intrinsic sympathomimetic activity (ISA: pindolol), lipophilicity (lipophilic: propranolol, metoprolol vs hydrophilic: atenolol, esmolol), and additional properties (alpha-blockade: labetalol, carvedilol). Perioperative considerations include the POISE trial warning against initiating high-dose beta-blockers immediately before surgery due to increased stroke risk, while continuing chronic beta-blocker therapy is recommended to prevent withdrawal phenomena. Esmolol is the agent of choice for acute intraoperative rate control due to its ultra-short half-life (9 minutes) via red blood cell esterase metabolism. Key adverse effects include bronchospasm (non-selective agents), masking of hypoglycaemia symptoms, bradycardia, heart block, and heart failure exacerbation. [1-8]

Pharmacology Overview

Drug Classification and Historical Context

Beta-adrenergic receptor antagonists represent one of the most important drug classes in cardiovascular medicine and perioperative care. The development of propranolol by Sir James Black in 1964 revolutionised the treatment of angina, hypertension, and arrhythmias, earning him the Nobel Prize in Physiology or Medicine in 1988. Since propranolol's introduction, numerous beta-blockers have been developed with varying selectivity, pharmacokinetic properties, and additional pharmacological actions. [9,10]

Beta-blockers are classified according to multiple pharmacological characteristics:

1. Receptor Selectivity:

2. Intrinsic Sympathomimetic Activity (ISA):

3. Lipophilicity:

4. Additional Properties:

Mechanism of Action

Beta-blockers are competitive antagonists at beta-adrenergic receptors, G protein-coupled receptors that normally respond to endogenous catecholamines (adrenaline and noradrenaline). The pharmacological effects depend on the receptor subtype blocked: [11-14]

Beta-1 Adrenoceptors (Cardiac):

Located predominantly in the heart, kidney (juxtaglomerular apparatus), and adipose tissue. Activation normally increases:

• Heart rate (positive chronotropy) via sinoatrial node
• Contractility (positive inotropy) via ventricular myocytes
• Conduction velocity (positive dromotropy) via AV node
• Renin release from juxtaglomerular cells

Beta-1 receptor blockade produces the primary therapeutic cardiovascular effects:

• Negative chronotropy: Reduced heart rate by 10-15 bpm typically
• Negative inotropy: Reduced myocardial contractility and oxygen demand
• Negative dromotropy: Slowed AV nodal conduction, prolonged PR interval
• Reduced renin release: Contributing to antihypertensive effect

Beta-2 Adrenoceptors (Peripheral):

Located in bronchial smooth muscle, vascular smooth muscle, skeletal muscle, liver, and pancreas. Activation normally causes:

• Bronchodilation
• Vasodilation (peripheral and coronary)
• Glycogenolysis and gluconeogenesis
• Skeletal muscle tremor
• Insulin release potentiation

Beta-2 receptor blockade produces adverse effects:

• Bronchoconstriction: Risk in asthma/COPD (non-selective agents)
• Vasoconstriction: Cold extremities, Raynaud's exacerbation
• Metabolic effects: Masked hypoglycaemia symptoms, impaired glucose tolerance
• Reduced tremor: May mask thyrotoxicosis symptoms

Beta-3 Adrenoceptors:

Located primarily in adipose tissue and bladder. Beta-3 activation increases lipolysis and bladder relaxation. Beta-blockers have minimal effect on beta-3 receptors, which are not clinically targeted by current agents.

Molecular Pharmacology

At the molecular level, beta-adrenoceptors couple to stimulatory G proteins (Gs) that activate adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple targets: [15-17]

Cardiac Effects of Beta-1 Stimulation:

1. L-type calcium channels: Increased calcium influx during depolarisation
2. Phospholamban: Increased SERCA2a activity, faster calcium reuptake into SR
3. Troponin I: Reduced calcium sensitivity, faster relaxation
4. Myosin binding protein C: Enhanced contractile function

Beta-blockers reverse these effects by competitive antagonism, reducing cAMP production and PKA activity.

Selectivity Considerations:

Beta-1 selectivity is relative, not absolute. At higher doses, "cardioselective" agents also block beta-2 receptors. The selectivity ratio for beta-1:beta-2 varies:

Pharmacokinetic Principles

Absorption and Bioavailability

Oral beta-blockers demonstrate variable bioavailability depending on lipophilicity and first-pass metabolism: [18-20]

Intravenous formulations (metoprolol, labetalol, esmolol, propranolol) bypass first-pass metabolism, providing 100% bioavailability.

Distribution

Volume of distribution varies with lipophilicity:

Lipophilic agents (propranolol, metoprolol) cross the blood-brain barrier readily, causing CNS effects including depression, fatigue, vivid dreams, and sleep disturbance. Hydrophilic agents (atenolol, esmolol) have minimal CNS penetration.

Metabolism and Elimination

Elimination pathways differ significantly between agents, with important implications for dosing in organ dysfunction: [21-23]

Hepatic Metabolism:

Lipophilic beta-blockers undergo extensive hepatic metabolism:

CYP2D6 polymorphisms significantly affect metoprolol and propranolol metabolism:

• Poor metabolisers (5-10% Caucasians): Increased drug exposure, enhanced effects
• Ultra-rapid metabolisers: Reduced efficacy, may need higher doses

Renal Elimination:

Hydrophilic agents are eliminated primarily unchanged by the kidneys:

Esmolol: Unique Metabolism

Esmolol is metabolised by red blood cell esterases (not plasma cholinesterases), producing an inactive acid metabolite. This results in: [24,25]

• Ultra-short half-life: 9 minutes
• Rapid offset: Effects dissipate within 10-20 minutes of cessation
• No accumulation with prolonged infusion
• No effect of hepatic or renal dysfunction on clearance
• Context-sensitive half-time remains constant

Half-Lives and Duration of Action

Individual Agents

Atenolol

Classification: Beta-1 selective, hydrophilic, no ISA

Pharmacokinetics:

• Oral bioavailability: 50-60%
• Protein binding: <5%
• Elimination: 85-100% renal (unchanged)
• Half-life: 6-9 hours

Clinical Use:

• Hypertension, angina, post-MI prophylaxis
• Thyrotoxicosis (adjunct)
• Migraine prophylaxis

Dosing:

• Oral: 25-100 mg daily
• No IV formulation in Australia

Advantages:

• Once-daily dosing
• Minimal CNS effects (hydrophilic)
• No hepatic metabolism concerns

Disadvantages:

• Requires renal dose adjustment
• Less evidence for mortality benefit than metoprolol/bisoprolol

Metoprolol

Classification: Beta-1 selective, lipophilic, no ISA

Pharmacokinetics:

• Oral bioavailability: 40-50%
• Protein binding: 12%
• Elimination: Hepatic (CYP2D6)
• Half-life: 3-7 hours

Clinical Use:

• Hypertension, angina, heart failure
• Acute coronary syndrome
• Perioperative rate control
• Migraine prophylaxis

Dosing:

• Oral: 25-200 mg BD (immediate release), 25-200 mg daily (XL)
• IV: 1-5 mg over 5 minutes, repeat to maximum 15 mg

Perioperative Considerations: [26,27]

• Continue chronic therapy through surgery
• IV metoprolol for acute rate control (1-5 mg boluses)
• Caution initiating high-dose therapy before non-cardiac surgery (POISE trial)

Esmolol

Classification: Beta-1 selective, hydrophilic, no ISA, ultra-short acting

Pharmacokinetics: [24,25]

• IV administration only
• Protein binding: 55%
• Metabolism: Red blood cell esterases
• Half-life: 9 minutes
• Onset: 2-10 minutes
• Offset: 10-20 minutes after cessation

Clinical Use:

• Acute perioperative rate control
• Intraoperative hypertension/tachycardia
• SVT, atrial fibrillation rate control
• Aortic dissection (with labetalol)
• Controlled hypotension

Dosing:

• Loading: 500 mcg/kg over 1 minute
• Infusion: 50-200 mcg/kg/min
• May repeat loading doses and titrate infusion
• Maximum: 300 mcg/kg/min (rarely needed)

Advantages:

• Rapid onset and offset (titratable)
• Ideal for haemodynamically unstable patients
• No hepatic or renal dose adjustment
• Not affected by pseudocholinesterase deficiency

Disadvantages:

• IV only, requires infusion pump
• Expensive compared to metoprolol
• May cause phlebitis at injection site

Labetalol

Classification: Non-selective beta-blocker with alpha-1 blockade (beta:alpha ratio ~7:1 IV, ~3:1 oral)

Pharmacokinetics: [28,29]

• Oral bioavailability: 25%
• Protein binding: 50%
• Elimination: Hepatic glucuronidation
• Half-life: 5-8 hours

Clinical Use:

• Hypertensive emergencies
• Pre-eclampsia/eclampsia (agent of choice in pregnancy)
• Aortic dissection
• Phaeochromocytoma (with alpha-blockade established)

Dosing:

• IV: 10-20 mg bolus, repeat every 10-20 minutes
• IV infusion: 0.5-2 mg/min
• Maximum: 300 mg total IV dose
• Oral: 100-400 mg BD

Unique Properties:

• Combined alpha and beta blockade reduces BP without reflex tachycardia
• Preferred in pregnancy (extensive safety data)
• Less reflex tachycardia than pure alpha-blockers
• Does not reduce uteroplacental blood flow at recommended doses

Obstetric Considerations: Labetalol is the first-line antihypertensive for severe hypertension in pregnancy (pre-eclampsia, eclampsia). The alpha-blocking component provides vasodilation while beta-blockade prevents reflex tachycardia. Fetal bradycardia and hypoglycaemia are potential concerns but rarely clinically significant at standard doses.

Propranolol

Classification: Non-selective, highly lipophilic, no ISA

Pharmacokinetics:

• Oral bioavailability: 25-35% (extensive first-pass)
• Protein binding: 90%
• Elimination: Hepatic (CYP2D6, CYP1A2)
• Half-life: 3-6 hours

Clinical Use:

• Thyrotoxicosis (blocks peripheral T4→T3 conversion)
• Portal hypertension prophylaxis
• Essential tremor
• Anxiety (situational)
• Migraine prophylaxis
• Phaeochromocytoma (with alpha-blockade)

Dosing:

• Oral: 10-80 mg TDS-QID
• IV: 1 mg over 1 minute, maximum 10 mg

Unique Properties:

• High lipophilicity allows CNS penetration (beneficial for anxiety, tremor)
• Inhibits peripheral deiodination of T4 to T3
• Membrane-stabilising activity at high doses

Disadvantages:

• Non-selective (bronchospasm risk)
• CNS effects (depression, fatigue, vivid dreams)
• Extensive hepatic metabolism, drug interactions

Carvedilol

Classification: Non-selective beta-blocker with alpha-1 blockade, antioxidant properties

Pharmacokinetics:

• Oral bioavailability: 25-35%
• Protein binding: 98%
• Elimination: Hepatic (CYP2D6, CYP2C9)
• Half-life: 7-10 hours

Clinical Use:

• Heart failure (mortality reduction)
• Hypertension
• Post-MI prophylaxis

Dosing:

• Heart failure: Start 3.125 mg BD, titrate to 25 mg BD
• Hypertension: 6.25-25 mg BD

Unique Properties:

• Proven mortality benefit in heart failure (COPERNICUS, COMET trials)
• Antioxidant activity may provide additional cardioprotection
• Alpha-blockade component aids vasodilation

Cardiovascular Effects

Heart Rate Effects

All beta-blockers reduce heart rate through beta-1 blockade at the sinoatrial node. The magnitude depends on: [1,2]

• Baseline sympathetic tone (greater effect with high catecholamine states)
• Selectivity (non-selective may have greater effect)
• Intrinsic sympathomimetic activity (ISA agents cause less resting bradycardia)

Typical Heart Rate Reduction:

• Rest: 5-10 bpm
• Exercise: 15-25 bpm (more pronounced)

Contractility Effects

Negative inotropy reduces myocardial oxygen demand but may precipitate heart failure in patients with impaired LV function. In chronic heart failure, however, beta-blockers provide mortality benefit through neurohormonal modulation. [30,31]

Conduction Effects

Beta-blockers slow conduction through the AV node (negative dromotropy): [32]

• Prolonged PR interval
• Useful for ventricular rate control in atrial fibrillation/flutter
• Risk of complete heart block with concurrent nodal-blocking agents

Blood Pressure Effects

Beta-blockers reduce blood pressure through multiple mechanisms:

1. Reduced cardiac output (acute effect)
2. Reduced renin release and RAAS suppression
3. Central nervous system effects (lipophilic agents)
4. Peripheral vasodilation (agents with alpha-blockade)

Respiratory Effects

Bronchospasm Risk

Non-selective beta-blockers antagonise beta-2 receptors in bronchial smooth muscle, potentially causing bronchoconstriction. This is clinically significant in: [5,6]

• Asthma (absolute contraindication for non-selective agents)
• COPD (relative contraindication)
• Reactive airway disease

Risk Stratification:

Beta-1 selectivity is lost at higher doses; even "cardioselective" agents may cause bronchospasm in susceptible patients.

Management of Beta-Blocker-Induced Bronchospasm:

• Salbutamol (high doses may be required)
• Ipratropium bromide (anticholinergic, not beta-agonist dependent)
• Adrenaline if severe
• Consider glucagon (positive inotrope/chronotrope independent of beta-receptors)

Metabolic Effects

Hypoglycaemia Masking

Beta-blockers mask the adrenergic symptoms of hypoglycaemia: [7,8]

• Tremor (beta-2 mediated)
• Tachycardia (beta-1 mediated)
• Anxiety, palpitations

Non-masked symptoms (useful for recognition):

• Sweating (cholinergic, not adrenergic)
• Confusion, cognitive impairment
• Hunger

Clinical Significance:

• Diabetic patients on insulin or sulfonylureas at risk
• Hypoglycaemia may be prolonged (impaired counter-regulatory response)
• Beta-1 selective agents preferred in diabetics
• Patient education essential

Glucose and Lipid Effects

Non-selective beta-blockers may impair glucose tolerance and worsen lipid profile:

• Reduced insulin secretion (beta-2 effect on pancreatic beta-cells)
• Increased triglycerides
• Decreased HDL cholesterol

Beta-1 selective agents and those with alpha-blockade (carvedilol) have more favourable metabolic profiles.

CNS Effects

Lipophilic beta-blockers (propranolol, metoprolol) penetrate the blood-brain barrier and may cause: [3,4]

• Depression (controversial, association in older literature)
• Fatigue, lethargy
• Sleep disturbance, vivid dreams, nightmares
• Cognitive impairment (elderly patients)

Hydrophilic agents (atenolol, esmolol) have minimal CNS penetration and fewer central effects.

Beneficial CNS Effects:

• Reduced anxiety (propranolol for performance anxiety)
• Essential tremor treatment
• Migraine prophylaxis

Perioperative Use

Continuation of Chronic Beta-Blocker Therapy

Patients on chronic beta-blocker therapy should continue their medication perioperatively: [26,27]

Rationale:

• Prevents withdrawal syndrome (rebound hypertension, tachycardia, ischaemia)
• Abrupt cessation associated with increased MI and mortality
• Give oral dose on morning of surgery with sip of water
• Convert to IV if prolonged nil by mouth

Withdrawal Syndrome: Chronic beta-blocker therapy causes beta-receptor upregulation. Abrupt cessation results in:

• Rebound hypertension
• Tachycardia
• Increased myocardial oxygen demand
• Precipitated angina, MI, arrhythmias

POISE Trial Caution

The POISE trial (PeriOperative Ischaemic Evaluation) examined beta-blocker initiation before non-cardiac surgery: [26]

Design:

• 8,351 patients with cardiovascular risk undergoing non-cardiac surgery
• Randomised to metoprolol XL 100 mg (started 2-4 hours pre-op) vs placebo
• High fixed-dose regimen without titration

Results:

Interpretation:

• Reduced MI but increased stroke and death
• Hypotension-related cerebral hypoperfusion likely mechanism for stroke
• Do NOT initiate high-dose beta-blockers immediately before surgery
• If initiating, start days-weeks before and titrate to HR/BP targets
• Continue chronic therapy

Current Recommendations (ESC/ACC Guidelines)

1. Continue chronic beta-blocker therapy perioperatively
2. Do not initiate high-dose beta-blockers within 24 hours of surgery
3. If starting beta-blocker pre-operatively:
   • Begin at least 2-7 days before surgery
   • Titrate to heart rate 60-70 bpm
   • Avoid hypotension (SBP >100 mmHg)
4. Consider beta-blockade in high-risk patients with inducible ischaemia

Acute Perioperative Rate Control

Indications for Acute Beta-Blockade

• Intraoperative tachycardia with haemodynamic compromise
• New-onset atrial fibrillation with rapid ventricular response
• Perioperative hypertension with tachycardia
• Aortic dissection (rate and BP control)
• Intubation response attenuation

Esmolol Dosing

Acute Rate Control:

• Loading: 500 mcg/kg over 1 minute (35 mg for 70 kg patient)
• Maintenance: Start 50 mcg/kg/min
• Titrate: Increase by 50 mcg/kg/min every 4-5 minutes
• Target: HR 60-80 bpm, SBP >90 mmHg
• Maximum: 200-300 mcg/kg/min

Intubation Response Attenuation:

• 0.5-1 mg/kg bolus 90-120 seconds before laryngoscopy
• Reduces hypertensive and tachycardic response to intubation

Metoprolol IV Dosing

Acute Rate Control:

• Initial: 1-2 mg IV over 2 minutes
• Repeat: Every 5 minutes to maximum 15-20 mg
• Target: HR 60-80 bpm
• Slower onset than esmolol, longer duration

Labetalol Dosing for Hypertension

Severe Hypertension/Aortic Dissection:

• Bolus: 10-20 mg IV over 2 minutes
• Repeat: Every 10-20 minutes as needed
• Infusion: 0.5-2 mg/min after bolus loading
• Maximum: 300 mg cumulative dose

Labetalol: Combined Alpha-Beta Blocking

Pharmacological Profile

Labetalol is a unique agent with combined alpha-1 and beta adrenoceptor antagonism: [28,29]

Receptor Ratio:

• IV administration: Beta:alpha = 7:1
• Oral administration: Beta:alpha = 3:1

Haemodynamic Effects:

• Reduces BP via alpha-1 blockade (vasodilation)
• Prevents reflex tachycardia via beta-1 blockade
• Does not significantly reduce cardiac output
• Maintains organ blood flow (cerebral, coronary, renal, uteroplacental)

Clinical Applications

Hypertensive Emergencies:

• Effective rapid BP reduction
• Less reflex tachycardia than pure vasodilators
• Useful for aortic dissection (combined with opioid for pain)

Pregnancy:

• First-line agent for severe hypertension in pre-eclampsia
• Extensive safety data in pregnancy (Category C)
• Does not reduce uteroplacental blood flow at recommended doses
• Fetal monitoring for bradycardia recommended

Phaeochromocytoma:

• Useful when alpha-blockade established
• Provides combined alpha-beta blockade
• Never use beta-blocker before adequate alpha-blockade (unopposed alpha stimulation)

Contraindications and Cautions

Absolute Contraindications

Relative Contraindications

Stable Heart Failure with Reduced EF

Despite negative inotropy, beta-blockers (carvedilol, bisoprolol, metoprolol succinate) provide mortality benefit in stable HFrEF. Key considerations:

• Start at very low doses
• Titrate slowly (weeks to months)
• Avoid initiation during acute decompensation
• Monitor for worsening symptoms

Drug Interactions

Pharmacodynamic Interactions

Pharmacokinetic Interactions

Calcium Channel Blockers Interaction

The combination of beta-blockers with non-dihydropyridine calcium channel blockers (verapamil, diltiazem) is particularly hazardous:

Mechanisms:

• Both cause negative chronotropy (SA node depression)
• Both cause negative dromotropy (AV node depression)
• Both cause negative inotropy

Risks:

• Severe bradycardia
• Complete heart block
• Heart failure
• Asystole (in severe cases)

Management:

• Avoid combination if possible
• If essential, use with extreme caution and monitoring
• Ensure pacing capability available

Indigenous Health Considerations

Aboriginal and Torres Strait Islander peoples experience disproportionately high rates of cardiovascular disease, including ischaemic heart disease, rheumatic heart disease, and heart failure. Beta-blockers are frequently required in this population, necessitating specific considerations for optimal prescribing and monitoring.

Pharmacokinetic Considerations: The prevalence of chronic kidney disease (CKD) is 3-4 times higher in Indigenous Australians than non-Indigenous Australians. For hydrophilic beta-blockers eliminated renally (atenolol, nadolol), dose reduction is essential in CKD. Preferred agents include those with hepatic metabolism (metoprolol, carvedilol) or esterase-dependent elimination (esmolol), which do not require renal dose adjustment. Regular monitoring of renal function is recommended when prescribing atenolol in Indigenous patients.

Comorbidity Management: High rates of type 2 diabetes in Indigenous communities increase the risk of hypoglycaemia masking with beta-blocker therapy. Patient education about non-adrenergic hypoglycaemia symptoms (sweating, confusion) is critical. Beta-1 selective agents are preferred to minimize metabolic effects. Heart failure with reduced ejection fraction, common following rheumatic heart disease, requires careful beta-blocker initiation at low doses with gradual titration.

Remote and Rural Access: Many Indigenous communities are located in remote areas with limited access to healthcare facilities. Once-daily agents (atenolol, bisoprolol) may improve adherence. Medication supply through the Pharmaceutical Benefits Scheme (PBS) Closing the Gap provisions may assist with cost. Aboriginal Health Workers and Aboriginal Health Practitioners play vital roles in medication education and monitoring. Telemedicine consultations can support remote initiation and dose titration.

Cultural Safety: Medication discussions should involve family and community members consistent with Indigenous concepts of collective health decision-making. Acknowledge traditional healing practices and their role alongside Western medication. Clear, non-judgmental communication about the importance of adherence and warning signs (bradycardia, breathlessness) supports safe beta-blocker use.

Māori Health Considerations (New Zealand): Māori populations also experience elevated cardiovascular disease rates. Similar principles apply regarding renal function assessment, diabetes management, and culturally appropriate care. Whānau involvement in health decisions is important, and pharmacists and kaiāwhina (community health workers) support medication understanding.

ANZCA Primary Exam Focus

Common MCQ Patterns

1. Receptor selectivity: Beta-1 selective agents (metoprolol, atenolol, esmolol) vs non-selective (propranolol, carvedilol, labetalol)
2. Esmolol metabolism: Red blood cell esterases (NOT plasma cholinesterases), ultra-short half-life 9 minutes
3. Labetalol ratio: Beta:alpha = 7:1 (IV), 3:1 (oral)
4. POISE trial: Reduced MI but increased stroke and mortality with acute high-dose metoprolol initiation
5. Lipophilicity and CNS effects: Propranolol (high CNS penetration) vs atenolol (low CNS penetration)
6. Bronchospasm: Non-selective agents contraindicated in asthma
7. Hypoglycaemia masking: Tachycardia and tremor masked, sweating preserved
8. Drug interactions: Verapamil/diltiazem with beta-blockers = severe bradycardia/heart block

Primary Viva Themes

• Choice of beta-blocker for specific clinical scenarios
• Management of beta-blocker overdose/toxicity
• Perioperative beta-blocker management (continuation vs initiation)
• Drug interactions with calcium channel blockers
• Esmolol pharmacology and clinical applications
• Labetalol in pregnancy/pre-eclampsia

Calculation Questions

Esmolol Loading Dose: 70 kg patient, loading dose 500 mcg/kg over 1 minute = 500 × 70 = 35,000 mcg = 35 mg

Esmolol Infusion Rate: 70 kg patient, infusion rate 100 mcg/kg/min, concentration 10 mg/mL (10,000 mcg/mL) = 100 × 70 = 7,000 mcg/min = 7 mg/min = 7 mg/min ÷ 10 mg/mL = 0.7 mL/min = 42 mL/hr

Assessment Content

SAQ Practice Question (20 marks)

Question:

A 58-year-old man with a history of hypertension, type 2 diabetes mellitus, and mild COPD presents for elective laparoscopic cholecystectomy. He takes metoprolol 50 mg twice daily, metformin 1000 mg twice daily, and tiotropium inhaler. His baseline blood pressure is 142/88 mmHg and heart rate is 68 bpm.

(a) Classify beta-adrenergic receptor antagonists according to receptor selectivity and lipophilicity. Provide two examples for each category. (4 marks)

(b) Describe the mechanism of action of beta-blockers at the molecular level. Explain how beta-1 receptor blockade produces the therapeutic cardiovascular effects. (5 marks)

(c) Discuss the perioperative management of this patient's metoprolol therapy, referencing relevant evidence including the POISE trial. (5 marks)

(d) Intraoperatively, the patient develops new-onset atrial fibrillation with a ventricular rate of 148 bpm and blood pressure 88/54 mmHg. Outline your approach to acute rate control, including drug selection and dosing. (6 marks)

---

Model Answer:

(a) Classification (4 marks)

Receptor Selectivity:

[1 mark for correct classification, 1 mark for examples of each]

Lipophilicity:

[1 mark for correct classification, 1 mark for examples of each]

(b) Mechanism of Action (5 marks)

Molecular Mechanism:

• Beta-adrenoceptors are G protein-coupled receptors [0.5]
• Coupled to stimulatory G protein (Gs) that activates adenylyl cyclase [0.5]
• Activation increases intracellular cyclic AMP (cAMP) [0.5]
• cAMP activates protein kinase A (PKA) [0.5]
• PKA phosphorylates L-type calcium channels, phospholamban, troponin I [0.5]

Beta-1 Blockade Effects:

• Negative chronotropy: Reduced SA node automaticity, decreased heart rate [0.5]
• Negative inotropy: Reduced calcium influx, decreased contractility [0.5]
• Negative dromotropy: Slowed AV conduction, prolonged PR interval [0.5]
• Reduced renin release: Decreased RAAS activation, lower BP [0.5]
• Reduced myocardial oxygen demand: Lower HR × BP product [0.5]

(c) Perioperative Metoprolol Management (5 marks)

Recommendation: Continue metoprolol perioperatively [1]

Rationale:

• Abrupt cessation causes withdrawal syndrome [0.5]
• Beta-receptor upregulation during chronic therapy [0.5]
• Withdrawal leads to rebound hypertension, tachycardia, ischaemia [0.5]
• Give oral dose on morning of surgery with sip of water [0.5]

POISE Trial Evidence:

• 8,351 patients randomised to metoprolol XL 100 mg vs placebo [0.5]
• Started 2-4 hours before non-cardiac surgery [0.25]
• Results: Reduced MI (4.2% vs 5.7%) but increased stroke (1.0% vs 0.5%) and mortality (3.1% vs 2.3%) [0.5]
• High fixed-dose, no titration, started immediately before surgery [0.25]

Current Recommendations:

• Continue chronic beta-blocker therapy [0.25]
• Do NOT initiate high-dose beta-blocker within 24 hours of surgery [0.25]
• If starting preoperatively, begin days-weeks before and titrate to targets [0.25]

(d) Acute Rate Control (6 marks)

Initial Assessment:

• Haemodynamically unstable (BP 88/54 mmHg) [0.5]
• New-onset AF with RVR (148 bpm) [0.5]
• Consider DC cardioversion if further deterioration [0.5]

Drug Selection:

• Esmolol preferred for this patient [1]
• Rationale: Ultra-short half-life (9 minutes), titratable, rapidly reversible if hypotension worsens [0.5]
• Caution with COPD but beta-1 selective at low doses [0.5]

Esmolol Dosing:

• Loading: 500 mcg/kg over 1 minute (approximately 35-40 mg for this patient) [0.5]
• Infusion: Start 50 mcg/kg/min [0.5]
• Titrate: Increase by 50 mcg/kg/min every 4-5 minutes [0.5]
• Target: HR 80-100 bpm, SBP >90 mmHg [0.5]

Supportive Measures:

• Fluid bolus (if not contraindicated) to support preload [0.25]
• Vasopressor (phenylephrine/metaraminol) if hypotension persists [0.25]
• Treat underlying cause (hypoxia, hypovolaemia, pain, electrolytes) [0.25]
• Consider amiodarone if beta-blocker ineffective or contraindicated [0.25]

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Examiner: A 45-year-old woman with pre-eclampsia at 34 weeks gestation requires urgent caesarean section. Her blood pressure is 178/112 mmHg despite oral labetalol 400 mg three times daily. How would you manage her blood pressure perioperatively?

Candidate:

Initial Assessment (2 marks):

"This patient has severe pre-eclampsia with poorly controlled hypertension despite oral labetalol therapy. My priorities are to:

1. Reduce blood pressure to prevent maternal complications (stroke, placental abruption, eclampsia)
2. Avoid precipitous BP drops that could compromise uteroplacental perfusion
3. Target BP of 140-150/90-100 mmHg for delivery"

Examiner: Why have you chosen labetalol for this patient?

Candidate:

Labetalol in Pre-eclampsia (3 marks):

"Labetalol is the first-line antihypertensive for severe hypertension in pregnancy for several reasons:

1. Combined alpha-beta blockade: Beta:alpha ratio approximately 7:1 intravenously. Alpha-1 blockade provides vasodilation, while beta-1 blockade prevents reflex tachycardia.

2. Haemodynamic profile: Reduces blood pressure without significantly reducing cardiac output or uteroplacental blood flow at recommended doses.

3. Safety in pregnancy: Extensive safety data, classified as FDA Category C. Does not cause fetal distress at standard doses.

4. Rapid onset IV: Can be titrated to effect with boluses or infusion.

Alternative agents include hydralazine (pure vasodilator, causes reflex tachycardia) and nifedipine (calcium channel blocker, risk of precipitous hypotension)."

Examiner: Please describe your IV labetalol dosing regimen.

Candidate:

IV Labetalol Dosing (3 marks):

"For acute BP control in pre-eclampsia:

Bolus Protocol:

• Initial: 20 mg IV over 2 minutes
• If inadequate response after 10 minutes: 40 mg IV
• Then 80 mg IV every 10-20 minutes if needed
• Maximum cumulative dose: 300 mg

Infusion Protocol (after bolus loading):

• 1-2 mg/min titrated to BP target
• Prepare: 200 mg in 200 mL (1 mg/mL)

Monitoring:

• Continuous BP monitoring (arterial line ideal)
• Continuous CTG for fetal heart rate
• Watch for maternal bradycardia (<60 bpm)"

Examiner: The patient's blood pressure is now 152/98 mmHg on labetalol infusion. During spinal anaesthesia, her BP drops to 78/50 mmHg. How do you manage this?

Candidate:

Management of Spinal Hypotension (3 marks):

"This is severe hypotension requiring immediate treatment:

Immediate Actions:

1. Left uterine displacement (improve venous return)
2. IV fluid bolus (500 mL crystalloid)
3. Vasopressor: Phenylephrine or ephedrine

Vasopressor Selection:

• Phenylephrine 50-100 mcg bolus (preferred for isolated hypotension)
• Ephedrine 5-10 mg bolus (if concurrent bradycardia)
• Metaraminol 0.5-1 mg bolus (alternative)

Consideration with Labetalol:

• The patient is on labetalol (alpha and beta blockade)
• Alpha-blockade may blunt phenylephrine response
• May need higher phenylephrine doses
• Consider ephedrine if poor response (indirect sympathomimetic)
• Avoid excessive doses causing uterine vasoconstriction"

Examiner: What are the potential fetal effects of beta-blockers in pregnancy?

Candidate:

Fetal Effects of Beta-Blockers (2 marks):

"Potential fetal effects include:

1. Fetal bradycardia: Beta-blockers cross the placenta and may cause fetal heart rate reduction. Usually mild and not clinically significant at standard labetalol doses.

2. Neonatal hypoglycaemia: Beta-blockade can impair neonatal glycogenolysis and counter-regulatory response. Monitor neonatal blood glucose.

3. Intrauterine growth restriction: Associated with chronic beta-blocker use (especially atenolol in first trimester), but labetalol evidence is more reassuring.

4. Respiratory depression: Theoretical risk, rarely clinically significant.

These effects are generally minimal with labetalol at recommended doses and are outweighed by the maternal benefits of BP control in severe pre-eclampsia."

Examiner: Can you compare labetalol with other beta-blockers in terms of their alpha-blocking properties?

Candidate:

Comparison (2 marks):

"Labetalol and carvedilol are the two clinically used beta-blockers with significant alpha-blocking activity:

The key distinction is that labetalol has predominantly beta-blocking activity with additional alpha-blockade, whereas carvedilol has more balanced alpha-beta antagonism.

Standard beta-blockers (metoprolol, atenolol, propranolol) have no clinically significant alpha-blocking activity and may cause unopposed alpha effects if given in phaeochromocytoma without prior alpha-blockade."

Total: 15 marks

---

References

1. Frishman WH. Beta-adrenergic blockers: pharmacology and clinical applications. Ann Intern Med. 1984;100(4):558-571. PMID: 6142747

2. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101(5):558-569. PMID: 10662755

3. Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288(3):351-357. PMID: 12117399

4. Ranchord AM, Spertus JA, Buchanan DM, et al. Initiation of beta-blocker therapy and depression after acute myocardial infarction. Am Heart J. 2016;174:37-42. PMID: 26995367

5. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137(9):715-725. PMID: 12416945

6. Morales DR, Jackson C, Lipworth BJ, et al. Adverse respiratory effect of acute beta-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014;145(4):779-786. PMID: 24202435

7. Barnett AH, Leslie D, Watkins PJ. Can insulin-treated diabetics be given beta-adrenergic blocking drugs? Br Med J. 1980;280(6219):976-978. PMID: 6106521

8. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA. 1997;278(1):40-43. PMID: 9207336

9. Black JW, Crowther AF, Shanks RG, et al. A new adrenergic beta-receptor antagonist. Lancet. 1964;1(7342):1080-1081. PMID: 14132613

10. Stapleton MP. Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology. Tex Heart Inst J. 1997;24(4):336-342. PMID: 9456487

11. Wachter SB, Gilbert EM. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology. 2012;122(2):104-112. PMID: 22832558

12. Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144(3):317-322. PMID: 15655528

13. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993;60(3):405-430. PMID: 7915424

14. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000;101(14):1634-1637. PMID: 10758041

15. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100(22):2210-2212. PMID: 10577992

16. Xiao RP, Zhu W, Zheng M, et al. Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci. 2004;25(7):358-365. PMID: 15219978

17. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res. 2003;93(10):896-906. PMID: 14615493

18. Regardh CG, Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet. 1980;5(6):557-569. PMID: 7002418

19. Mason WD, Winer N, Kochak G, et al. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther. 1979;25(4):408-415. PMID: 34429

20. Cruickshank JM. The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J. 1980;100(2):160-178. PMID: 6105819

21. Lennard MS, Silas JH, Freestone S, et al. Oxidation phenotype—a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307(25):1558-1560. PMID: 7144837

22. Kirchheiner J, Heesch C, Bauer S, et al. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2004;76(4):302-312. PMID: 15470329

23. McDevitt DG. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J. 1987;8 Suppl M:9-14. PMID: 2897302

24. Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clin Pharmacokinet. 2012;51(6):347-356. PMID: 22515556

25. Quon CY, Mai K, Patil G, Stampfli HF. Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos. 1988;16(3):425-428. PMID: 2900742

26. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371(9627):1839-1847. PMID: 18479744

27. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. J Am Coll Cardiol. 2014;64(22):e77-e137. PMID: 25091544

28. MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193-219. PMID: 6310529

29. Lund-Johansen P. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. Drugs. 1984;28 Suppl 2:35-50. PMID: 6151379

30. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334(21):1349-1355. PMID: 8614419

31. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007. PMID: 10376614

32. Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professionals. Circulation. 1996;93(6):1262-1277. PMID: 8653857

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols in clinical practice.